The markups helped the PBMs reap $7.3 billion from 2017 to 2022, the FTC found. The PBMs—owned by insurers Cigna, CVS Health and UnitedHealth Group—are supposed to help keep drug costs low for ...
During a roughly five-year span, CVS Health, Cigna, and UnitedHealth benefited the most from increasing prices for generic drugs that treated illnesses such as HIV and cancer. Some of the price hikes ...
The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants, and other conditions and procedures, the FTC said. The report ...
Some results have been hidden because they may be inaccessible to you